A chess program that learns from human error might be better at working with people or negotiating with them.
It took about 50 years for computers to eviscerate humans in the venerable game of chess. A standard smartphone can now play the kind of moves that make a grandmaster’s head spin. But one artificial intelligence program is taking a few steps backward, to appreciate how average humans play—blunders and all.
The AI chess program, known as Maia, uses the kind of cutting-edge AI behind the best superhuman chess-playing programs. But instead of learning how to destroy an opponent on the board, Maia focuses on predicting human moves, including the mistakes they make. Read More
Daily Archives: February 17, 2021
MIT 6.S191: Recurrent Neural Networks
MIT Introduction to Deep Learning | 6.S191
Causal network models of SARS-CoV-2 expression and aging to identify candidates for drug repurposing
Given the severity of the SARS-CoV-2 pandemic, a major challenge is to rapidly repurpose existing approved drugs for clinical interventions. While a number of data-driven and experimental approaches have been suggested in the context of drug repurposing, a platform that systematically integrates available transcriptomic, proteomic and structural data is missing. More importantly, given that SARS-CoV-2 pathogenicity is highly age-dependent, it is critical to integrate aging signatures into drug discovery platforms. We here take advantage of large-scale transcriptional drug screens combined with RNA-seq data of the lung epithelium with SARS-CoV-2 infection as well as the aging lung. To identify robust druggable protein targets, we propose a principled causal framework that makes use of multiple data modalities. Our analysis highlights the importance of serine/threonine and tyrosine kinases as potential targets that intersect the SARS-CoV-2 and aging pathways. By integrating transcriptomic, proteomic and structural data that is available for many diseases, our drug discovery platform is broadly applicable. Rigorous in vitro experiments as well as clinical trials are needed to validate the identified candidate drugs. Read More
Rick's Cafe AI 